Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.3K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

570
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
570
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.5K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.5K
Lineage Commitment01:21

Lineage Commitment

3.5K
Commitment is the  process whereby stem cells:
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4.

Apoptosis : an international journal on programmed cell death·2026
Same author

Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Blood cancer journal·2026
Same author

MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.

British journal of haematology·2026
Same author

Left Atrial Strain Correlation with Functional Capacity and Additional Prognostic Value of Speckle Tracking in Cardiac Amyloidosis: A Prospective, Single-Center Study.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Oct 18, 2025

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.6K

Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?

Anna Suska1, David H Vesole2, Jorge J Castillo3

  • 1Department of Hematology, Jagiellonian University Medical College, Kopernika 17, Krakow 31-501, Poland.

Clinical Hematology International
|October 1, 2021
PubMed
Summary

Plasma cell leukemia (PCL) is a rare, aggressive blood cancer. Early treatment with novel agents and stem cell transplant improves survival, though prognosis remains poor, especially for secondary PCL.

Keywords:
Plasma cell leukemiachemotherapyclinical trialsnovel agentsplasma cell dyscrasiaprognostic indexstem cell transplantation

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.9K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K

Related Experiment Videos

Last Updated: Oct 18, 2025

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.6K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.9K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K

Area of Science:

  • Hematology
  • Oncology
  • Cancer Biology

Background:

  • Plasma cell leukemia (PCL) is an aggressive hematological malignancy.
  • It involves uncontrolled proliferation of plasma cells (PCs) in bone marrow and blood.
  • PCL is classified as primary (de novo) or secondary (from multiple myeloma).

Purpose of the Study:

  • To define Plasma Cell Leukemia (PCL) and its subtypes.
  • To outline current treatment strategies and challenges.
  • To discuss the prognosis and risk stratification of PCL.

Main Methods:

  • Literature review of PCL diagnosis, classification, and treatment.
  • Analysis of treatment outcomes and survival data.
  • Discussion of response evaluation criteria and prognostic indices.

Main Results:

  • PCL diagnosis requires circulating PCs >2.0 × 10^9/L or >20% of leukocytes.
  • Primary and secondary PCL are distinct clinical and biological entities.
  • Conventional chemotherapy yields poor survival (6.8–12.6 months); novel agents and SCT improve outcomes but survival remains low.
  • Secondary PCL has an extremely poor prognosis (1-month OS).

Conclusions:

  • Immediate treatment with proteasome inhibitors, immunomodulators, and SCT is recommended for eligible patients.
  • The rarity of PCL limits clinical trials and necessitates careful response evaluation.
  • The PCL prognostic index aids in risk stratification for this challenging malignancy.